January 4th 2024
Posters from San Antonio Breast Cancer Symposium 2023 found that combination therapies featuring trastuzumab biosimilars and other common cancer medicines were safe and effective in patients with breast cancer.
December 14th 2023
Two Taiwanese posters presented at the San Antonio Breast Cancer Symposium (SABCS) 2023 annual meeting evaluated the real-world implications of using trastuzumab biosimilars, particularly Ogivri (trastuzumab-dkst) in patients with HER2-postive breast cancer.
December 14th 2021
In metastatic breast cancer (mBC) resistant to multiple lines, Herzuma (a trastuzumab biosimilar) plus gedatolisib, an mTOR/PI3K signaling pathway inhibitor, demonstrated value.
December 13th 2021
After a switch to a biosimilar, patients and their oncologists may not always agree on how well the switch was described or whether the patient felt involved.
December 9th 2021
The trial included "drifted" (nonstandard) reference product, forcing a stratified analysis to yield relevant data.
December 8th 2021
A trastuzumab biosimilar candidate demonstrated equivalence to Herceptin in patients with early-stage human epidermal growth factor receptor 2 (HER2)–breast cancer.
January 31st 2021
Here are the top 5 biosimilar articles from SABCS 2020.
January 9th 2021
Pharmacokinetic (PK) parameters matched up with those of reference trastuzumab in an extended analysis of data from the HERITAGE trial.
January 4th 2021
Among patients treated for metastatic breast cancer, 40% switched to ABP 980.
December 15th 2020
In little over 1 year of use in patients with breast cancer, trastuzumab biosimilars have seen rapid growth in uptake.
